Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer

John Harlow, a seasoned pharmaceutical executive, joins Melinta as Chief Commercial Officer under the leadership of President and Chief Executive Officer, Christine Ann Miller. With the new addition of Mr. Harlow, Melinta expects to build upon its existing platform and enhance its world-class antibiotics portfolio with additional products that address therapeutic areas of critical need.

“The success of our organization lies heavily on our impact in the marketplace as well as the support and dedication of our valued team,” said Ms. Miller. “We are excited to welcome John to Melinta. His proven track record in launching and re-launching businesses all while building high performing teams will help us achieve our strategic priorities.”

Mr. Harlow joins Melinta from Baudax Bio where he served as Chief Commercial Officer leading their launch of a non-opioid pain medication for post-operative patients. At Baudaux, he was instrumental in building their marketing, sales, market access and operations departments while launching innovative approaches to address the market challenges from the COVID-19 pandemic.

Prior to Baudax Bio, Mr. Harlow held executive positions at Recro Pharma, Endo Pharmaceuticals and Shionogi, Inc. In these roles, he transformed organizational development for internal teams and successfully launched new products into the marketplace. In addition, Mr. Harlow consistently achieved record sales goals for each organization.

“I am honored to join the Melinta organization in the middle of such great momentum,” said Mr. Harlow. “I’m excited to be a member of an esteemed leadership team who takes pride and cares for the people who support them every day. I look forward to delivering upon the continued growth and expansion of Melinta’s portfolio as we reimagine the future together.” 

About Melinta Therapeutics

Melinta Therapeutics, LLC is the largest pure-play antibiotics company, dedicated to providing innovative therapies to people impacted by acute and 
life-threatening illnesses. It currently markets four antibiotics: Baxdela® (delafloxacin), Vabomere® (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. This portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.

Contact Information

Susan Blum
(312) 767-0296
info@melinta.com